These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 11929795)

  • 41. Chelation therapy in beta-thalassemia: an optimistic update.
    Giardina PJ; Grady RW
    Semin Hematol; 2001 Oct; 38(4):360-6. PubMed ID: 11605171
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Iron chelation therapy for transfusional iron overload: a swift evolution.
    Musallam KM; Taher AT
    Hemoglobin; 2011; 35(5-6):565-73. PubMed ID: 21910602
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Desferrioxamine-caffeine (DFCAF) as a cell permeant moderator of the oxidative stress caused by iron overload.
    Alta EC; Goswami D; Machini MT; Silvestre DM; Nomura CS; Espósito BP
    Biometals; 2014 Dec; 27(6):1351-60. PubMed ID: 25265871
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The iron-loaded gerbil model revisited: effects of deferoxamine and deferiprone treatment.
    Hershko C; Link G; Konijn AM; Huerta M; Rosenmann E; Reinus C
    J Lab Clin Med; 2002 Jan; 139(1):50-8. PubMed ID: 11873245
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A time-cost augmented economic evaluation of oral deferasirox versus infusional deferoxamine [corrected] for patients with iron overload in South Korea.
    Kim J; Kim Y
    Value Health; 2009; 12 Suppl 3():S78-81. PubMed ID: 20586988
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combined therapy with deferoxamine and deferiprone.
    Kattamis A
    Ann N Y Acad Sci; 2005; 1054():175-82. PubMed ID: 16339663
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.
    Kolnagou A; Economides C; Eracleous E; Kontoghiorghes GJ
    Hemoglobin; 2008; 32(1-2):41-7. PubMed ID: 18274982
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The iron chelating agent, deferoxamine detoxifies Fe(Salen)-induced cytotoxicity.
    Umemura M; Kim JH; Aoyama H; Hoshino Y; Fukumura H; Nakakaji R; Sato I; Ohtake M; Akimoto T; Narikawa M; Tanaka R; Fujita T; Yokoyama U; Taguri M; Okumura S; Sato M; Eguchi H; Ishikawa Y
    J Pharmacol Sci; 2017 Aug; 134(4):203-210. PubMed ID: 28779994
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN; Kontoghiorghes GJ
    Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development of iron chelators to treat iron overload disease and their use as experimental tools to probe intracellular iron metabolism.
    Richardson DR; Ponka P
    Am J Hematol; 1998 Aug; 58(4):299-305. PubMed ID: 9692394
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload.
    Borgna-Pignatti C; Franchini M; Gandini G; Vassanelli A; De Gironcoli M; Aprili G
    Haematologica; 1998 Sep; 83(9):788-90. PubMed ID: 9825575
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A non-human primate model for the study of oral iron chelators.
    Wolfe LC; Nicolosi RJ; Renaud MM; Finger J; Hegsted M; Peter H; Nathan DG
    Br J Haematol; 1989 Jul; 72(3):456-61. PubMed ID: 2765410
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
    Ha SY; Chik KW; Ling SC; Lee AC; Luk CW; Lam CW; Ng IO; Chan GC
    Hemoglobin; 2006; 30(2):263-74. PubMed ID: 16798652
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antimalarial effect of HBED and other phenolic and catecholic iron chelators.
    Yinnon AM; Theanacho EN; Grady RW; Spira DT; Hershko C
    Blood; 1989 Nov; 74(6):2166-71. PubMed ID: 2508794
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Modulation of deferoxamine toxicity and clearance by covalent attachment to biocompatible polymers.
    Hallaway PE; Eaton JW; Panter SS; Hedlund BE
    Proc Natl Acad Sci U S A; 1989 Dec; 86(24):10108-12. PubMed ID: 2481311
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Enhanced iron removal from liver parenchymal cells in experimental iron overload: liposome encapsulation of HBED and phenobarbital administration.
    Rahman YE; Cerny EA; Lau EH; Carnes BA
    Blood; 1983 Jul; 62(1):209-13. PubMed ID: 6407548
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Subcutaneous bolus injection of deferoxamine is an alternative method to subcutaneous continuous infusion.
    Yarali N; Fişgin T; Duru F; Kara A; Ecin N; Fitoz S; Erden I
    J Pediatr Hematol Oncol; 2006 Jan; 28(1):11-6. PubMed ID: 16394886
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload.
    Franchini M; Gandini G; de Gironcoli M; Vassanelli A; Borgna-Pignatti C; Aprili G
    Blood; 2000 May; 95(9):2776-9. PubMed ID: 10779420
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Therapeutic mechanism of combined oral chelation therapy to maximize efficacy of iron removal in transfusion-dependent thalassemia major - a pilot study.
    Lin CH; Chen X; Wu CC; Wu KH; Song TS; Weng TF; Hsieh YW; Peng CT
    Expert Rev Hematol; 2019 Apr; 12(4):265-272. PubMed ID: 30920854
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mechanism-Based Pharmacokinetic Modeling of Absorption and Disposition of a Deferoxamine-Based Nanochelator in Rats.
    Jones G; Zeng L; Kim J
    Mol Pharm; 2023 Jan; 20(1):481-490. PubMed ID: 36378830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.